Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,444 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pharmacodynamics Clear all

Conditions: Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions: PXS-5505; Drug
Lead sponsor: Syntara; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas

Conditions: Healthy Volunteers, Sickle Cell Disease
Interventions: FT-4202/Placebo; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV
Interventions: Ritonavir, Cobicistat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Atropine, Propranolol, Normal Saline; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced/Metastatic Colorectal Adenocarcinoma
Interventions: BAY 3771249, Cetuximab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Phoenix, Arizona • Duarte, California • San Diego, California + 4 more

Conditions: Renal Impairment, Hemodialysis
Interventions: INCB000928; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Miami, Florida + 2 more

Conditions: Healthy
Interventions: HM10760A or placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: US, California

Conditions: Alzheimer Disease
Interventions: DNL747, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more

Conditions: End Stage Renal Disease
Interventions: Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Kidney Transplantation
Interventions: CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Renal Insufficiency, Healthy
Interventions: Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Carboplatin, Durvalumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ezogabine, Placebo; Drug
Lead sponsor: Brian Wainger; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more

Conditions: Healthy Participants
Interventions: BMS-986322, BMS-986322 Placebo, famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
Interventions: ticagrelor; Drug
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ORJ-001, Placebo; Drug · Other
Lead sponsor: Oorja Bio, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Doral, Florida • DuBois, Pennsylvania

Conditions: Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Interventions: JUR-003; Biological
Lead sponsor: Juri Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Lake Success, New York • Nashville, Tennessee + 1 more

Conditions: Bariatric Surgery, Obesity
Interventions: Apixaban; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostatic Neoplasms
Interventions: PF-06755992, PF-06755990, TDS-IM Electroporation Device, Tremelimumab, PF-06801591, PF-06753512; Biological · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Tucson, Arizona • New Haven, Connecticut • Bethesda, Maryland + 10 more

Conditions: Healthy Volunteers
Interventions: ASP1128, Placebo; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo matching Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Chula Vista, California • San Diego, California • Torrance, California + 9 more

Conditions: Cannabis Use, Tobacco Use, Cigarette Smoking
Interventions: THC 30mg, THC 5mg, THC 0mg, Cigarette Full Nicotine, Cigarette Reduced Nicotine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

Analysis of Atropine and Propranolol Induced Changes

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Study of ORJ-001 for the Treatment of IPF

JUR-003 in Adult Patients With Metastatic Prostate Cancer

Apixaban Pharmacokinetics in Bariatric Patients (APB)

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Effect of Cannabis on Cigarette Use Behavior